CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

NARecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2028

Conditions
Lymphoma, B-Cell
Interventions
DRUG

chimeric antigen receptor gene modified T cells

The rate of intravenous infusion of CD30 CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.

Trial Locations (1)

Unknown

RECRUITING

Shanxi Bethune Hospital, Taiyuan

All Listed Sponsors
lead

Shanxi Bethune Hospital

OTHER

NCT06850285 - CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma | Biotech Hunter | Biotech Hunter